Resveratrol and vitamin D: Significant potential interpretative problems arising from their mutual processes, interactions and effects

Medical Hypotheses

Volumn 77, Issue 5, 2011, Pages 765-772

  Hayes, Daniel P ^a  

^a BROOKLYN HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PHYTOALEXIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; VITAMIN D;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOCHEMISTRY; DIET SUPPLEMENTATION; DNA SYNTHESIS; DRUG ACTIVITY; DRUG MECHANISM; HEART PROTECTION; HORMESIS; ISCHEMIA; NERVE DEGENERATION; PARKINSON DISEASE; STROKE; SUN EXPOSURE;

DRUG INTERACTIONS; HUMANS; MODELS, THEORETICAL; STILBENES; VITAMIN D;

EID: 80054003467     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.07.033     Document Type: Article

References (132)

1. Namasivayam N. Chemoprevention in experimental animals. Ann N Y Acad Sci 2011, 1215:60-71.
2. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
3. Mukhopadhyay P., Pacher P., Das D.K. MicroRNA signatures of resveratrol in the ischemic heart. Ann N Y Acad Sci 2011, 1215:109-116.
4. van de Wiel A., de Lange D.W. Cardiovascular risk is more related to drinking pattern than to the type of alcoholic drinks. Neth J Med 2008, 66:468-473.
5. Klatsky A.L. Alcohol and cardiovascular health. Physiol Behav 2010, 100:76-81.
6. Rimm E.B., Klatsky A.L., Grobbee D., Stampfer M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits?. Br Med J 1996, 312:731-736.
7. Gronbaek M. Epidemiologic evidence for the cardio-protective effects associated with consumption of alcoholic beverages. Pathophysiology 2004, 10:83-92.
8. Shukla Y., Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 2011, 1215:1-8.
9. Patel K.R., Scott E., Brown V.A., Gescher A.J., Steward W.P., Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011, 1215:161-169.
10. Norman A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008, 88(Suppl.):491S-499S.
11. Hayes D.P. The protection afforded by vitamin D against low radiation damage. Int J Low Radiat 2008, 5:368-394.
12. Hayes D.P. Cancer protection related to solar ultraviolet radiation, altitude and vitamin D. Med Hypotheses 2010, 74:378-382.
13. Hayes D.P. Influenza pandemics, solar activity cycles, and vitamin D. Med Hypotheses 2010, 74:831-834.
14. Hayes D.P. Vitamin D and ageing. Biogerontology 2010, 11:1-16.
15. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80:1678S-1688S.
16. Heaney R.P., Recker R.R., Grote J., Horst R.L., Armas L.A. Vitamin D3 is more potent than Vitamin D2 in humans. J Clin Endocrinol Metab 2011, 96:E447-E452.
17. De Luca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80(Suppl. 6):1689S-1696S.
18. Holick M.F. The vitamin D solution 2010, Hudson Street Press, New York, New York.
19. Hollis B.W. Assessment of circulating 25(OH)D and 1, 25(OH)2D: emergence as clinically important diagnostic tools. Nutr Rev 2007, 65:S87-S90.
20. Hayes D.P. Nutritional hormesis. Eur J Clin Nutr 2007, 61:147-159.
21. Hayes D.P. Adverse effects of nutritional inadequacy and excess: a hormetic model. Am J Clin Nutr 2008, 88(Suppl.):578S-581S.
22. Hayes D.P. Nutritional hormesis and aging. Dose Response 2010, 8(8):10-15.
23. Chiang E.C., Shen S., Kengeri S.S., et al. Defining the optimal selenium dose for prostate cancer risk reduction: insight from the U-shaped relationship between selenium status, DNA damage, and apoptosis. Dose Response 2010, 8:285-300.
24. Calabrese E.J., Mattson M.P., Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 2010, 29:980-1015.
25. Hayes D.P. Commentary on 'resveratrol commonly displays hormesis: occurrence and biomedical significance'. Hum Exp Toxicol 2010, 29:1018-1020.
26. Calabrese E.J., Baldwin L.A. U-shaped dose-responses in biology, toxicology, and public health. Ann Rev Public Health 2001, 22:15-33.
27. Constant J. Alcohol, ischemic heart disease, and the French paradox. Clin Cardiol 1997, 29:420-425.
28. Juhasz B., Mukherjee S., Das D.K. Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol 2010, 15:e134-e138.
29. de Almeida L.M., Pineiro C.C., Leite M.C., et al. Resveratrol increase glutamate uptake, glutathione content, and S100B secretion in cortical astrocyte cultures. Cell Mol Neurobiol 2007, 27:661-668.
30. Das D.K., Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006, 6:36-47.
31. Mukherjee S., Dudley J.I., Das D.K. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010, 8:478-500.
32. Harmon C.S., Nevins T.D. Biphasic effect of 1,25-dihydroxyvitamin D3 on human hair growth and hair fiber production in whole organ cultures. J Invest Dermatol 1994, 103:318-322.
33. Lissoos T.W., Beno D.W., Davis B.H. 1,25-Dihydroxyvitain D3 activates Raf kinase and Raf perinuclear translocation via a protein kinase C-dependent pathway. J Biol Chem 1993, 268:25132-25138.
34. Mitsuhashi T., Morris R.C., Ives H.E. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991, 87:1889-1895.
35. Svendsen M.L., Daneels G., Geysen J., Binderup L., Kragballe K. Proliferation and differentiation of culture human keratinocytes is modulated by 1,25(OH)2D3 and synthetic vitamin D3 analogues in a cell density-, calcium- and serum-dependent manner. Pharmacol Toxicol 1997, 80:49-56.
36. Thong H.Y., Maibach H.I. Hormesis [biological effects of low level exposure (belle)] and dermatology. Dose Response 2008, 6:1-15.
37. Stumpf W.E. The dose makes the medicine. Drug Discov Today 2006, 11:550-555.
38. World Health Organization International Agency for Research on Cancer. In: Vitamin D and cancer: IARC working group reports, vol. 5. Lyon, France: World Health Organization International Agency for Research on Cancer; 2008.
39. Toner C.D., Davis C.D., Milner J.A. The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc 2010, 110:1492-1500.
40. Toner C.D., Davis C.D., Milner J.A. Authors' response. J Am Diet Assoc 2011, 111:366.
41. Grant W.B. UVB-vitamin D-cancer hypothesis. J Am Diet Assoc 2011, 111:365-366.
42. Wietze J.A., Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitain D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003, 84(2-3):149-157.
43. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993, 90:7915-7922.
44. Ofodile O.N. Cardiovascular disease could be contained based on currently available data!. Dose Response 2006, 4:225-254.
45. Seifried H.E., McDonald S.S., Anderson D.E., Greenwald P., Milner J.A. The antioxidant conundrum in Cancer. Cancer Res 2003, 63:4295-4298.
46. Salganik R.I. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 2001, 20(5 Suppl.):4645-4728.
47. Abete P., Calabrese E., Ji L.L., et al. Mild stress and healthy aging: perspectives for human beings. Mild stress and healthy aging 2008, 171-183. Springer, Berlin. E. Le Bourg, S.I.S. Rattan (Eds.).
48. Chatterjee M. Vitamin D and genomic stability. Mutat Res 2001, 2001(475):69-87.
49. Lin A.M., Fan S.F., Yang D.S., Hsu L.L., Yang C.H. Zinc-induced oxidative apoptosis in substantia nigra of rat brain: neuronprotection by vitamin D3. Free Radic Biol Med 2003, 34:1416-1425.
50. Bao B.-Y., Ting H.-J., Hsu J.-W., Lee Y.-F. Protective role of 1α,25-dihydroxyvitamin D3 against sensitive oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 2008, 122:2699-2706.
51. Losa G.A. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 2003, 33:818-823.
52. Yen G.C., Duh P.D., Lin C.W. Effect of resveratrol and 4-hexylresorcicol in hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 2003, 37:509-514.
53. Sardar S., Chakraborty A., Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. Int J Vitam Nutr Res 1996, 66:39-45.
54. Miura T., Muraoka S., Ikeda N., Watanabe M., Fujimoto Y. Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol 2000, 86:203-208.
55. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
56. Tsujimoto J., Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005, 12(Suppl. 2):1528-1534.
57. Mathew R., White E. Why sick cells produce tumors: the protective role of autophagy. Autophagy 2007, 3:502-505.
58. Roach H.I., Aigner T., Kouri J.B. Chondroptosis: a variant of apoptotic cell death in chondrocytes?. Apoptosis 2004, 9:265-277.
59. Shintani T., Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 2004, 306(5698):990-995.
60. Eskelinen E.L. Doctor Jekyll and Mister Hyde: autophagy can promote both cell survival and cell death. Cell Death Differ 2005, 12(Suppl. 2):1468-1472.
61. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24:2783-2840.
62. Slater A.F., Nobel C.S., Orrenius S. The role of intracellular oxidants in apoptosis. Biochim Biophys Acta 1995, 1271:59-62.
63. Hampton M.B., Orrenius S. Redox regulation of apoptotic cell death in the immune system. Toxicol Lett 1998, 102-103:355-358.
64. Johnson T.M., Yu Z.-X., Ferrans V.J., Lowenstein R.A., Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 1996, 93:11848-11852.
65. Warner H.R., Sierra F. Models of accelerated ageing can be informative about the molecular mechanisms of ageing and/or age-related pathology. Mech Ageing Dev 2003, 124:581-587.
66. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994, 124:1-6.
67. Ylikomi T., Laaksi I., Lou Y.-R., et al. Antiproliferative action of vitamin D. Vitam Horm 2002, 64:357-406.
68. Danielsson C., Mathiasen I.S., James S.Y., et al. Sensitive induction of apoptosis by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity. J Cell Biochem 1997, 66:552-562.
69. Gupta S.C., Kannappan R., Reuter S., et al. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011, 1215:150-160.
70. Singletary K., Milner J. Diet, autophagy, and cancer: a review. Cancer Epidemiol Biomarkers Prev 2008, 17:1596-1610.
71. Yue Z., Jin S., Yang C., Levine A.J., Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003, 100:15077-15082.
72. Hoyer-Hansen M., Jaattela M. AMP-activated protein kinase: a universal regulator of autophagy. Autophagy 2007, 3:381-383.
73. Mathiasen I.S., Sergeev I.N., Bastholm L., Elling F., Norman A.W., Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem 2002, 277:30738-30745.
74. Swerdlow S., Distehorst C.W. Bcl-2 regulated calcium signals as common mediators of both apoptosis and autophagy. Dev Cell 2007, 12:178-179.
75. Fremont L. Biological effects of resveratrol. Life Sci 2000, 66:663-673.
76. Richard T., Pawlus A.D., Iglesias M.-L., et al. Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 2011, 1215:103-108.
77. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006, 545:51-64.
78. Bursch W., Ellinger A. Autophagy - a basic mechanism and a potential role for neurodegeneration. Folia Neuropath 2005, 43:297-310.
79. Ravikumar B., Rubinsztein D.C. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?. Mol Aspects Med 2006, 27:520-527.
80. Williams A., Jahreiss L., Sarkar S., et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006, 76:89-101.
81. Stumpf W.E., O'Brien L.P. The 1,25(OH)2 vitamin D3 sites of action in the brain. An autographic study. Histochemistry 1987, 87:393-406.
82. Regulska M., Leskiewicz M., Budziszewska B., et al. Involvement of P13-K in neuroprotective effects of 1,25-dihydroxyvitamin D3 analogue - PRI-2191. Pharmacol Rep 2006, 58:900-907.
83. Landfield P.W., Cadwallader-Neal L. Long-tem treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging 1998, 19:469-477.
84. Wang Y., Chiang Y.H., Su T.P., et al. Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000, 39:873-880.
85. Ibi M., Sawada H., Nakanishi M., et al. Protective effects of 1 alpha,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001, 40:761-771.
86. Wang Y.K., Wu Y.N., Cherng T.L., et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001, 904:67-75.
87. Grant W.B. Does vitamin D reduce the risk of dementia?. J Alzheimers Dis 2009, 17:151-159.
88. Marino M.J., Conn P.J. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 2006, 6:98-102.
89. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002, 13:100-105.
90. Shinpo K., Kilkuchi S., Sasaki H., Moriwaka F., Tashiro K. Effect of 1,25-dihydroxyvitamin D3 on cultured dopaminergic neurons to the combined toxicity caused by l-buthionine sulfoximine and 1-methyl-4-phenylpyridine. Neurosci Res 2000, 62:374-382.
91. Quincozes-Santos A., Gottfried C. Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann N Y Acad Sci 2011, 1215:72-78.
92. Gurusamy N., Ray D., Lekli I., Das D.K. Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infracted myocardium. J Cell Mol Med 2010, 14:2235-2239.
93. Lekli I., Ray D., Mukherjee S., et al. Coordinated autophagy with resveratrol and I3-tocotrienol confers synergetic cardioprotection. J Cell Mol Med 2010, 14:2506-2518.
94. Petrovski G., Gurusamy N., Das D.K. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011, 1215:22-33.
95. Zittermann A., Schleithoff S.S., Koerfer R., et al. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005, 94:483-492.
96. Li Y.C., Kong J., Chen Z.-F., Liu S.Q., Cao L.-P. 1,25-Dihydroxyvitamin D3 is a negative regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
97. Li Y.C. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003, 88:327-331.
98. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
99. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
100. Poole K.E., Loveridge N., Barker P.J., et al. Reduced vitamin D in acute stroke. Stroke 2006, 37:243-245.
101. Fahrleitner A., Dobnig H., Obernosterer A., et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med 2002, 17:663-669.
102. Holick M.F. Sunlight and vitamin D; both good for cardiovascular health. J Gen Intern Med 2002, 17:733-735.
103. Zittermann A., Schleithoff S.S., Tenderich G., et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure. J Am Coll Cardiol 2003, 41:105-112.
104. Zittermann A., Schleithoff S.S., Gotting C., et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008, 10:321-327.
105. Vieth R., Kimball S. Vitamin D in congestive heart failure. Am J Clin Nutr 2006, 83:731-732.
106. Canning M.O., Grotenhuis K., de Wit H., Ruwhof C., Drexhage H.A. 1-α,25-Dihydroxyvitamin D3 (1,25(OH)D3) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001, 145:351-357.
107. Zhu Y., Mahon B.D., Froicu M., Cantorna M.T. Calcium and 1 alpha,25-dihydroxyvitamin D3 target TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005, 35:217-224.
108. Rigby W.F., Denome S., Fanger M.W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydoroxyvitamin D3; specific inhibition at the local level of messenger RNA. J Clin Invest 1987, 79:1659-1664.
109. Wu J.W., Hsieh T.C. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 2011, 1215:16-21.
110. Csiszar A., Labinskyy N., Smith K., Rivera A., Orosz Z., Ungvari Z. Vasculoprotective effects of anti-tumor necrosis factor-α treatment in aging. Am J Pathol 2007, 170:388-398.
111. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Korfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
112. Chow S.-E., Hshu Y.-C., Wang J.-S., Chen J.-K. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 2007, 102:1520-1527.
113. Zhang H., Zhang J., Ungvari Z., Zhang C. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009, 29:1164-1171.
114. Csiszar A., Smith K., Labinskyy N., Orosz Z., Rivera A., Ungvari Z. Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition. Am J Physiol Heart Circ Physiol 2006, 291:H1694-H1699.
115. Jablonski K.L., Chonchol M., Pierce G.L., Walker A.E., Seals D.R. 25-hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011, 57:63-69.
116. Zhang H., Morgan B., Potter B.J., Ma L., Dellsperger K.C., et al. Resveratrol improves left ventricular diastolic regulation of type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010, 299:H985-H994.
117. Cardus A., Parisi E., Gallego C., Aldea M., Fernandez E., Valdivielso J.M. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle proliferation through a VEGF-mediated pathway. Kidney Int 2006, 69:1377-1384.
118. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001, 15:1798-1800.
119. Athar M., Back J.H., Tang X., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007, 224:274-283.
120. Lamprecht S.A., Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003, 3:601-614.
121. van Leeuwen J.P.T.M., Pols H.A.P. Vitamin D: anticancer and differentiation. Vitamin D 1997, 1089-1105. Academic Press, San Diego. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
122. Ohnishi T., Takahashi A., Ohnishi K. Studies about space radiation promote new fields in radiation biology. J Radiat Res (Tokyo) 2002, 43(Suppl.):S7-S12.
123. Sengottuvelan M., Senthilkumar R., Nalini N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta 2006, 1760:1175-1183.
124. Jones G.M., Sanford K.K., Parshad R., Gantt R., Price F.M., Tarone R.E. Influence of added catalase on chromosome stability and neoplastic transformation of mouse cells in culture. Br J Cancer 1985, 52:583-590.
125. Christkos S., Liu Y. Biological actions and mechanisms of action of calbindin in the process of apoptosis. J Steroid Biochem Mol Biol 2004, 89-90:401-404.
126. Dorrie J., Gerauer H., Wachter Y., Zunino S.J. Resveratrol induces apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 2001, 61:4731-4739.
127. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signaling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
128. Sengottuvelan M., Deeptha K., Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem Biol Interact 2009, 181:193-201.
129. Sengottuvelan M., Deeptha K., Nalini N. Resveratrol attenuates 1,2-dimethylhydrazine (DMH) induced glycoconjugate abnormalities during various stages of colon carcinogenesis. Phytother Res 2009, 23:1154-1158.
130. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1α,25-dihydroxyvitamin D3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
131. Matsumoto H., Iino Y., Koibuchi Y., et al. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 1999, 6:349-352.
132. Reynolds A.R. Potential relevance of bell-shaped and U-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2010, 8:253-284.